The new article “Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies” by Oleg Demin Jr, Ying Ou, Galina Kolesova, Dmitry Shchelokov, Alexander Stepanov, Veronika Musatova, Sri Sahasranaman, Yating Zhao, Xiangyu Liu, Zhiyu Tang, William D. Hanley was published in CPT: Pharmacometrics & Systems Pharmacology Journal on February 12, 2025. The work was supported by BeiGene.
Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, highlights “The aim of this work was to simulate the target occupancy of three approved covalent BTK inhibitors, not only in PBMC but also in tissues such as lymph nodes and bone marrow. Consistent with observed clinical data, the model predicted that zanubrutinib 160 mg twice daily resulted in higher trough BTK occupancy compared with approved doses of ibrutinib and acalabrutinib. Remarkably, due to the mechanistic description of BTK turnover and its inhibition, the model can potentially be used to simulate target occupancy for reversible BTK inhibitors and even BTK protein levels during treatment with targeted protein degraders. Moreover, BTK occupancy in non-oncology indications can also be predicted. The development of this versatile and highly reproducible model was enabled by the application of our established software infrastructure, namely, the Heta compiler and HetaSimulator.”
Learn more about Heta Project: hetalang.github.io
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | August 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
1.
02 Aug 2021 16:17
InSysBio to take part in PharmSci360 2021
InSysBio announces its participation in AAPS 2021 PHARMSCI 360 which is to be held in Pennsylvania Convention Center, Philadelphia, PA, and Online 17-20 October, 2021. InSysBio team is going to present the update at the Virtual Booth (VB1) and 2 posters in frames of the Conference
|
3
|
4
|
5
|
6
1.
06 Aug 2021 15:38
InSysBio to participate in Biomarkers for Alzheimer’s Disease Summit
InSysBio will take part in Annual Biomarkers for Alzheimer’s Disease Summit, Digital Event which is going to be held August 24-26, 2021. InSysBio will present its Neurodegeneration modeling issues and Alzheimer’s Disease Platform update at its Virtual Booth! Moreover, Tatiana Karelina, Head of Neurodegenerative Diseases Modeling Team, will give a talk
|
7
|
8
|
|
9
|
10
|
11
1.
11 Aug 2021 15:50
InSysBio to launch its OpenSource HetaSimulator project
The new platform is a part of Heta-based QSP modeling infrastructure
[Moscow – 11.08.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, now presents HetaSimulator. It is a part of Heta project that embraces three components. HetaSimulator is an OpenSource simulation and parameters estimation platform for the Heta modeling language.
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
1.
18 Aug 2021 10:49
InSysBio to take part in PAGE 2021
InSysBio announces its participation in PAGE 2021 Online meeting which is to be held on the 2nd, 3rd, 6th, and 7th of September 2021. InSysBio team is going to present its latest development at the Virtual Exhibition e-booth and six posters
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
